Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Toll-like Receptor 4 Signaling and Downstream Neutrophilic Inflammation Mediate Endotoxemia-Enhanced Blood-Labyrinth Barrier Trafficking.

Urdang ZD, Bills JL, Cahana DY, Muldoon LL, Neuwelt EA.

Otol Neurotol. 2019 Sep 16. doi: 10.1097/MAO.0000000000002447. [Epub ahead of print]

PMID:
31568132
2.

Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.

Barajas RF, Hamilton BE, Schwartz D, McConnell HL, Pettersson DR, Horvath A, Szidonya L, Varallyay CG, Firkins J, Jaboin JJ, Kubicky CD, Raslan AM, Dogan A, Cetas JS, Ciporen J, Han SJ, Ambady P, Muldoon LL, Woltjer R, Rooney WD, Neuwelt EA.

Neuro Oncol. 2019 Mar 18;21(4):517-526. doi: 10.1093/neuonc/noy160.

PMID:
30277536
3.

Sodium Thiosulfate and Cisplatin-Induced Hearing Loss.

Brock PR, Maibach R, Neuwelt EA.

N Engl J Med. 2018 Sep 20;379(12):1181. doi: 10.1056/NEJMc1809501. No abstract available.

PMID:
30231227
4.

Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma.

Ambady P, Szidonya L, Firkins J, James J, Johansson K, White T, Jezierski C, Doolittle ND, Neuwelt EA.

Leuk Lymphoma. 2019 Feb;60(2):515-518. doi: 10.1080/10428194.2018.1480771. Epub 2018 Jul 22. No abstract available.

PMID:
30033836
5.

Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.

Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA.

N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109.

6.

Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.

Varallyay CG, Nesbit E, Horvath A, Varallyay P, Fu R, Gahramanov S, Muldoon LL, Li X, Rooney WD, Neuwelt EA.

J Magn Reson Imaging. 2018 Aug;48(2):441-448. doi: 10.1002/jmri.25943. Epub 2018 Jan 4.

7.

Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas.

Horváth A, Varallyay CG, Schwartz D, Toth GB, Netto JP, Barajas R, Várallyay P, Szidonya L, Firkins J, Youngers E, Fu R, Ambady P, Bogner P, Neuwelt EA.

Magn Reson Med. 2018 Jul;80(1):224-230. doi: 10.1002/mrm.27028. Epub 2017 Dec 4.

8.

Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency.

Dósa E, Heltai K, Radovits T, Molnár G, Kapocsi J, Merkely B, Fu R, Doolittle ND, Tóth GB, Urdang Z, Neuwelt EA.

Fluids Barriers CNS. 2017 Oct 3;14(1):26. doi: 10.1186/s12987-017-0075-0.

9.

Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol.

Netto JP, Iliff J, Stanimirovic D, Krohn KA, Hamilton B, Varallyay C, Gahramanov S, Daldrup-Link H, d'Esterre C, Zlokovic B, Sair H, Lee Y, Taheri S, Jain R, Panigrahy A, Reich DS, Drewes LR, Castillo M, Neuwelt EA.

Neurosurgery. 2018 Jun 1;82(6):770-780. doi: 10.1093/neuros/nyx357. Review.

10.

Pseudo-extravasation rate constant of dynamic susceptibility contrast-MRI determined from pharmacokinetic first principles.

Li X, Varallyay CG, Gahramanov S, Fu R, Rooney WD, Neuwelt EA.

NMR Biomed. 2017 Nov;30(11). doi: 10.1002/nbm.3797. Epub 2017 Sep 8.

11.

Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors.

Ambady P, Wu YJ, Walker JM, Kersch C, Pagel MA, Woltjer RL, Fu R, Muldoon LL, Neuwelt EA.

Cancer Gene Ther. 2017 Aug;24(8):348-357. doi: 10.1038/cgt.2017.27. Epub 2017 Jul 28.

12.

High αv Integrin Level of Cancer Cells Is Associated with Development of Brain Metastasis in Athymic Rats.

Wu YJ, Pagel MA, Muldoon LL, Fu R, Neuwelt EA.

Anticancer Res. 2017 Aug;37(8):4029-4040.

13.

Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.

Ambady P, Fu R, Netto JP, Kersch C, Firkins J, Doolittle ND, Neuwelt EA.

Fluids Barriers CNS. 2017 Jun 2;14(1):16. doi: 10.1186/s12987-017-0064-3.

14.

What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent.

Varallyay CG, Toth GB, Fu R, Netto JP, Firkins J, Ambady P, Neuwelt EA.

AJNR Am J Neuroradiol. 2017 Jul;38(7):1297-1302. doi: 10.3174/ajnr.A5188. Epub 2017 May 11.

15.

Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.

Toth GB, Varallyay CG, Horvath A, Bashir MR, Choyke PL, Daldrup-Link HE, Dosa E, Finn JP, Gahramanov S, Harisinghani M, Macdougall I, Neuwelt A, Vasanawala SS, Ambady P, Barajas R, Cetas JS, Ciporen J, DeLoughery TJ, Doolittle ND, Fu R, Grinstead J, Guimaraes AR, Hamilton BE, Li X, McConnell HL, Muldoon LL, Nesbit G, Netto JP, Petterson D, Rooney WD, Schwartz D, Szidonya L, Neuwelt EA.

Kidney Int. 2017 Jul;92(1):47-66. doi: 10.1016/j.kint.2016.12.037. Epub 2017 Apr 20. Review.

16.

Comprehensive Review of the ThinkFirst Injury Prevention Programs: A 30-Year Success Story for Organized Neurosurgery.

Youngers EH, Zundel K, Gerhardstein D, Martínez M, Bertrán C, Proctor MR, Spatola MA, Neuwelt EA.

Neurosurgery. 2017 Sep 1;81(3):416-421. doi: 10.1093/neuros/nyx053. Review.

PMID:
28368495
17.

Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.

Netto JP, Schwartz D, Varallyay C, Fu R, Hamilton B, Neuwelt EA.

Fluids Barriers CNS. 2016 Dec 20;13(1):23. doi: 10.1186/s12987-016-0047-9.

18.

Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group.

Knight KR, Chen L, Freyer D, Aplenc R, Bancroft M, Bliss B, Dang H, Gillmeister B, Hendershot E, Kraemer DF, Lindenfeld L, Meza J, Neuwelt EA, Pollock BH, Sung L.

J Clin Oncol. 2017 Feb;35(4):440-445. doi: 10.1200/JCO.2016.69.2319. Epub 2016 Dec 12. Erratum in: J Clin Oncol. 2017 Apr 1;35(10):1141.

19.

The Translational Significance of the Neurovascular Unit.

McConnell HL, Kersch CN, Woltjer RL, Neuwelt EA.

J Biol Chem. 2017 Jan 20;292(3):762-770. doi: 10.1074/jbc.R116.760215. Epub 2016 Dec 5. Review.

20.

Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.

Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, Pollock BH, Ramdas J, Lange B, Van Hoff D, VanSoelen ML, Wiernikowski J, Neuwelt EA, Sung L.

Lancet Oncol. 2017 Jan;18(1):63-74. doi: 10.1016/S1470-2045(16)30625-8. Epub 2016 Dec 1. Erratum in: Lancet Oncol. 2017 Jun;18(6):e301.

21.

Outwitting the Blood-Brain Barrier.

Neuwelt E, Ambady P, Muldoon L, McConnell H, Doolittle N.

Oncology (Williston Park). 2016 Nov 15;30(11):963, 966-7. No abstract available.

22.

Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations.

Hamilton BE, Woltjer RL, Prola-Netto J, Nesbit GM, Gahramanov S, Pham T, Wagner J, Neuwelt EA.

J Neurooncol. 2016 Sep;129(2):301-9. doi: 10.1007/s11060-016-2175-0. Epub 2016 Jul 8.

PMID:
27393348
23.

Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific.

McConnell HL, Schwartz DL, Richardson BE, Woltjer RL, Muldoon LL, Neuwelt EA.

Nanomedicine. 2016 Aug;12(6):1535-42. doi: 10.1016/j.nano.2016.03.009. Epub 2016 Apr 9.

24.

Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!

Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, Schlegel U, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M, Glantz M.

J Clin Oncol. 2016 May 20;34(15):1829-30. doi: 10.1200/JCO.2015.65.0879. Epub 2016 Mar 21. No abstract available.

25.

Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.

Muldoon LL, Pagel MA, Netto JP, Neuwelt EA.

J Neurooncol. 2016 Feb;126(3):447-54. doi: 10.1007/s11060-015-2000-1. Epub 2015 Dec 2.

PMID:
26694547
26.

Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults.

Muehe AM, Feng D, von Eyben R, Luna-Fineman S, Link MP, Muthig T, Huddleston AE, Neuwelt EA, Daldrup-Link HE.

Invest Radiol. 2016 Apr;51(4):221-227. doi: 10.1097/RLI.0000000000000230.

27.

Dose-Dependent Neurotoxicity (Seizures) Due to Deposition of Gadolinium-based Contrast Agents in the Central Nervous System.

Muldoon LL, Neuwelt EA.

Radiology. 2015 Dec;277(3):925-6. doi: 10.1148/radiol.2015151028. No abstract available.

PMID:
26599933
28.

Interactions between αv-Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain.

Lal S, Kersch C, Beeson KA, Wu YJ, Muldoon LL, Neuwelt EA.

PLoS One. 2015 Jul 29;10(7):e0131842. doi: 10.1371/journal.pone.0131842. eCollection 2015.

29.

Mapping human brain capillary water lifetime: high-resolution metabolic neuroimaging.

Rooney WD, Li X, Sammi MK, Bourdette DN, Neuwelt EA, Springer CS Jr.

NMR Biomed. 2015 Jun;28(6):607-23. doi: 10.1002/nbm.3294. Epub 2015 Apr 27.

30.
31.

Unsanctifying the sanctuary: challenges and opportunities with brain metastases.

Puhalla S, Elmquist W, Freyer D, Kleinberg L, Adkins C, Lockman P, McGregor J, Muldoon L, Nesbit G, Peereboom D, Smith Q, Walker S, Neuwelt E.

Neuro Oncol. 2015 May;17(5):639-51. doi: 10.1093/neuonc/nov023. Review.

32.

Primary CNS lymphoma: a landmark trial and the next steps.

Neuwelt EA, Schiff D.

Neurology. 2015 Mar 24;84(12):1194-5. doi: 10.1212/WNL.0000000000001407. Epub 2015 Feb 25. No abstract available.

PMID:
25716361
33.

Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival.

Gahramanov S, Varallyay C, Tyson RM, Lacy C, Fu R, Netto JP, Nasseri M, White T, Woltjer RL, Gultekin SH, Neuwelt EA.

CNS Oncol. 2014 Nov;3(6):389-400. doi: 10.2217/cns.14.42.

34.

N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models.

Muldoon LL, Wu YJ, Pagel MA, Neuwelt EA.

J Neurooncol. 2015 Feb;121(3):433-40. doi: 10.1007/s11060-014-1657-1. Epub 2014 Nov 21.

35.

Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.

Doolittle ND, Muldoon LL, Culp AY, Neuwelt EA.

Adv Pharmacol. 2014;71:203-43. doi: 10.1016/bs.apha.2014.06.002. Epub 2014 Aug 22. Review.

36.

Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis.

Neuwelt AJ, Nguyen TM, Fu R, Bubalo J, Tyson RM, Lacy C, Gahramanov S, Nasseri M, Barnes PD, Neuwelt EA.

CNS Oncol. 2014 Jul;3(4):267-73. doi: 10.2217/cns.14.24.

37.

Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.

Nasseri M, Gahramanov S, Netto JP, Fu R, Muldoon LL, Varallyay C, Hamilton BE, Neuwelt EA.

Neuro Oncol. 2014 Aug;16(8):1146-54. doi: 10.1093/neuonc/not328. Epub 2014 Feb 11.

38.

Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder.

Nakamoto BK, Shikuma CM, Ogata-Arakaki D, Umaki T, Neuwelt EA, Shiramizu BT, Chow DC, Parikh NI, Kallianpur KJ, Hamilton BE.

J Neurovirol. 2013 Dec;19(6):601-5. doi: 10.1007/s13365-013-0213-7. Epub 2013 Oct 16.

39.

Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery.

Doolittle ND, Dósa E, Fu R, Muldoon LL, Maron LM, Lubow MA, Tyson RM, Lacy CA, Kraemer DF, Butler RW, Neuwelt EA.

J Clin Oncol. 2013 Nov 1;31(31):4026-7. doi: 10.1200/JCO.2013.52.7747. Epub 2013 Oct 7. No abstract available.

40.

Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors.

Neuwelt AJ, Nguyen T, Wu YJ, Donson AM, Vibhakar R, Venkatamaran S, Amani V, Neuwelt EA, Rapkin LB, Foreman NK.

Pediatr Blood Cancer. 2014 Jan;61(1):120-7. doi: 10.1002/pbc.24602. Epub 2013 Aug 17.

41.

Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL.

Farrell BT, Hamilton BE, Dósa E, Rimely E, Nasseri M, Gahramanov S, Lacy CA, Frenkel EP, Doolittle ND, Jacobs PM, Neuwelt EA.

Neurology. 2013 Jul 16;81(3):256-63. doi: 10.1212/WNL.0b013e31829bfd8f. Epub 2013 Jun 14.

42.

Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma.

Wu YJ, Neuwelt AJ, Muldoon LL, Neuwelt EA.

Anticancer Res. 2013 Jun;33(6):2391-400.

43.

Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.

Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel U, Rogowski S, Fu R, Dósa E, Illerhaus G, Kraemer DF, Muldoon LL, Calabrese P, Hedrick N, Tyson RM, Jahnke K, Maron LM, Butler RW, Neuwelt EA.

Neurology. 2013 Jul 2;81(1):84-92. doi: 10.1212/WNL.0b013e318297eeba. Epub 2013 May 17.

44.

Inhibition of SUR1 decreases the vascular permeability of cerebral metastases.

Thompson EM, Pishko GL, Muldoon LL, Neuwelt EA.

Neoplasia. 2013 May;15(5):535-43.

45.

High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle.

Varallyay CG, Nesbit E, Fu R, Gahramanov S, Moloney B, Earl E, Muldoon LL, Li X, Rooney WD, Neuwelt EA.

J Cereb Blood Flow Metab. 2013 May;33(5):780-6. doi: 10.1038/jcbfm.2013.36. Epub 2013 Mar 13.

46.

Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.

Gahramanov S, Muldoon LL, Varallyay CG, Li X, Kraemer DF, Fu R, Hamilton BE, Rooney WD, Neuwelt EA.

Radiology. 2013 Mar;266(3):842-52. doi: 10.1148/radiol.12111472. Epub 2012 Nov 30.

47.

A 67-year-old woman receiving tumor necrosis factor α inhibitor therapy presenting with neurologic dysfunction.

Garg N, Woltjer R, Hamilton B, Neuwelt EA, Rosenbaum JT.

Arthritis Care Res (Hoboken). 2013 Apr;65(4):658-65. doi: 10.1002/acr.21882. No abstract available.

48.

The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma.

Thompson EM, Whitney NL, Wu YJ, Neuwelt EA.

J Neurosurg Pediatr. 2013 Jan;11(1):60-7. doi: 10.3171/2012.9.PEDS12268. Epub 2012 Oct 19.

49.

Immunologic privilege in the central nervous system and the blood-brain barrier.

Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, Engelhardt B, Hallenbeck JM, Lonser RR, Ohlfest JR, Prat A, Scarpa M, Smeyne RJ, Drewes LR, Neuwelt EA.

J Cereb Blood Flow Metab. 2013 Jan;33(1):13-21. doi: 10.1038/jcbfm.2012.153. Epub 2012 Oct 17. Review.

50.

Ferumoxytol-enhanced MRI to Image Inflammation within Human Brain Arteriovenous Malformations: A Pilot Investigation.

Hasan DM, Amans M, Tihan T, Hess C, Guo Y, Cha S, Su H, Martin AJ, Lawton MT, Neuwelt EA, Saloner DA, Young WL.

Transl Stroke Res. 2012 Jul;3(Suppl 1):166-73. doi: 10.1007/s12975-012-0172-y.

Supplemental Content

Loading ...
Support Center